In an Arthritis & Rheumatology analysis of data on 60,980 US adults with autoimmune rheumatic conditions who developed COVID-19 between December 2020 and August 2024, those who received booster or… read more.
The risk of being hospitalised for flu or pneumonia can be reduced with a high-dose flu vaccine for older people with chronic lung disease, according to the combined… read more.
Gilead Sciences, Inc. announced that the FDA approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults… read more.
Pfizer Inc. and BioNTech SE announced that the FDA has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant… read more.
The results show a need for nuanced communication between doctors and patients. “Always finish your antibiotics” is no longer considered medical best practice for all conditions. Surprised? You’re… read more.
Men are more likely than women to catch tuberculosis (TB), finds a new study led by UCL (University College London) researchers. Globally, men account for around two-thirds of… read more.
The first evidence that night work and chronic insomnia may increase the risk of developing long COVID comes from a new study led by ISGlobal, a centre supported by “la Caixa” Foundation,… read more.
Emily P. Hyle, MD, and Kenneth A. Freedberg, MD, of the Medical Practice Evaluation Center within the Department of Medicine at Mass General Brigham, are the lead and senior authors of a… read more.
Bavarian Nordic A/S announced that the European Commission has adopted the recent Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending the approval of a type… read more.
Moderna, Inc. announced that the FDA has approved Mflusiva (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows… read more.
Sanofi announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants… read more.
Merck announced that the FDA has accepted a supplemental Biologics License Application (sBLA) for Enflonsia (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
